Transdermal Delivery of Selexipag Metabolite
AssigneeSamos Pharmaceuticals, LLC
InventorAgis Kydonieus
Life of this patent
Estimating the term…
Abstract
Compositions, devices and methods for the transdermal delivery of drugs that are potent vasorelaxants and inhibitors of human platelet aggregation are disclosed. These drugs bind to the IP receptor on endothelial and platelet cells and they are useful in the treatment of pulmonary arterial hypertension and other diseases where vasoconstriction is an issue. The compositions, methods and devices pertain particularly to the transdermal delivery of the selexipag metabolite ACT 333679.
Claims20
A transdermal patch comprising ACT 333679 in a sufficient amount to deliver ACT 333679 for an extended period of time for the treatment of pulmonary arterial hypertension and/or other diseases of the vascular system.
A composition for topical application comprising ACT 333679 for the delivery of therapeutic levels of ACT 333679 for an extended period of time for the treatment of pulmonary arterial hypertension and/or other diseases of the vascular system.
A method of administering ACT 333679 to an individual for the treatment of pulmonary arterial hypertension and/or another disease of the vascular system, comprising:
- a. Identifying an individual for whom administration of the ACT 33679 is indicated;
- and
- b. topically applying to the individual one or more of
- i. a transdermal patch comprising ACT 333679 in a sufficient amount to deliver ACT 333679 for an extended period;
- and
- ii. A composition for topical application comprising ACT 333679 in a sufficient amount to topically deliver the ACT 333679 for an extended period.
Dependencies are inferred from the claim text.